(12) United States Patent
`Wright et al.
`
`USOO6264987B1
`(10) Patent No.:
`US 6,264,987 B1
`(45) Date of Patent:
`Jul. 24, 2001
`
`METHOD FOR PREPARING
`MICROPARTICLES HAVING A SELECTED
`POLYMERMOLECULAR WEIGHT
`
`Inventors: Steven G. Wright, Madeira; Michael
`E. Rickey, Loveland; J. Michael
`Ramstack, Lebanon; Shawn L. Lyons;
`Joyce M. Hotz, both of Cincinnati, all
`of OH (US)
`Assignee: Alkermes Controlled Therapeutics
`Inc. II, Cambridge, MA (US)
`Subject to any disclaimer, the term of this
`patent is extended or adjusted under 35
`U.S.C. 154(b) by 0 days.
`
`Notice:
`
`Appl. No.: 09/575,075
`Filed:
`May 19, 2000
`Int. Cl." ............................ A61K 9/14; A61 K9/50:
`B01J 13/02
`U.S. Cl. .......................... 424/489: 424/497; 424/484;
`264/41; 264/46; 427/213.3; 427/213.36
`Field of Search ..................................... 424/489, 497;
`264/41, 46; 427/213.3, 213.36
`
`(56)
`
`References Cited
`
`U.S. PATENT DOCUMENTS
`5,654,008 * 8/1997 Herbert et al........................ 424/489
`
`* cited by examiner
`
`G. Reister;
`
`Primary Examiner Thurman K. Page
`Assistant Examiner Blessing Fubara
`(74) Attorney, Agent, or Firm- Andrea
`Covington & Burling
`(57)
`ABSTRACT
`A method for preparing microparticles having a Selected
`polymer molecular weight. The hold time and temperature
`of a Solution containing a nucleophilic compound and a
`polymer having a starting molecular weight are controlled in
`order to control the molecular weight of the polymer in the
`finished microparticle product. In this manner, a Selected
`polymer molecular weight in the finished microparticle
`product can be achieved from a variety of Starting material
`molecular weights.
`
`50 Claims, 4 Drawing Sheets
`
`(54)
`
`(75)
`
`(73)
`
`(*)
`
`(21)
`(22)
`(51)
`(52)
`(58)
`
`
`
`y = 5.6599x + 17,142
`R2 = 0.7461
`
`TIME, HRS
`
`AMN1018
`IPR of Patent No. 7,919,499
`
`

`

`U.S. Patent
`
`Jul. 24, 2001
`
`Sheet 1 of 4
`
`US 6,264,987 B1
`
`
`
`e
`
`S3
`
`SS
`
`S.
`
`Cd
`co
`
`C
`ca
`
`%'SSOMW
`
`AMN1018
`IPR of Patent No. 7,919,499
`
`

`

`U.S. Patent
`
`Jul. 24, 2001
`
`Sheet 2 of 4
`
`US 6,264,987 B1
`
`
`
`ce
`
`s
`
`g
`
`St.
`
`S
`
`co
`ca
`
`ld
`
`% 'SSO MW
`
`Sp
`
`ld
`
`C
`
`AMN1018
`IPR of Patent No. 7,919,499
`
`

`

`U.S. Patent
`
`Jul. 24, 2001
`
`Sheet 3 of 4
`
`US 6,264,987 B1
`
`
`
`d
`en
`
`S
`
`2
`
`Sp
`
`s
`
`co
`gd
`re-
`
`d
`re-
`r
`
`C
`en
`rea
`
`Co
`co
`re-
`
`ed
`cC
`
`C
`cC
`
`Ced
`s
`
`S
`
`(OOOX)
`H5)MWOTOW
`
`AMN1018
`IPR of Patent No. 7,919,499
`
`

`

`U.S. Patent
`
`##2|
`
`ZZZ
`
`º->
`
`
`
`
`
`AMN1018
`IPR of Patent No. 7,919,499
`
`

`

`1
`METHOD FOR PREPARING
`MICROPARTICLES HAVING A SELECTED
`POLYMERMOLECULAR WEIGHT
`BACKGROUND OF THE INVENTION
`1. Field of the Invention
`The present invention relates to preparation of micropar
`ticles. More particularly, the present invention relates to a
`method and an apparatus for preparing microparticles hav
`ing a Selected polymer molecular weight.
`2. Related Art
`A variety of methods is known by which compounds can
`be encapsulated in the form of microparticles. It is particu
`larly advantageous to encapsulate a biologically active or
`pharmaceutically active agent within a biocompatible, bio
`degradable wall forming material (e.g., a polymer) to pro
`vide Sustained or delayed release of drugs or other active
`agents. In these methods, the material to be encapsulated
`(drugs or other active agents) is generally dissolved,
`dispersed, or emulsified, using Stirrers, agitators, or other
`dynamic mixing techniques, in one or more Solvents con
`taining the wall forming material. Solvent is then removed
`from the microparticles and thereafter the microparticle
`product is obtained.
`One variable that affects the in vitro and in vivo perfor
`mance of the microparticle product is the molecular weight
`of the polymer or polymeric matrix material in the final
`microparticle product. Molecular weight affects drug release
`characteristics. The molecular weight of a polymer influ
`ences the biodegradation rate of the polymer. For a diffu
`Sional mechanism of active agent release, the polymer
`should remain intact until all of the active agent is released
`from the microparticles, and then degrade. The active agent
`can also be released from the microparticles as the poly
`meric matrix material bioerodes. By an appropriate Selection
`of polymeric materials a microparticle formulation can be
`made in which the resulting microparticles exhibit both
`diffusional release and biodegradation release properties.
`This is useful in affording multiphasic release patterns.
`It has been reported that the molecular weight of the
`poly(D.L-lactide) (“DL-PL”) component of microcapsules
`containing up to 50% thioridazine free base decreased
`during fabrication, and in dissolution rate Studies of the
`microcapsule (see Maulding, H.V. et al., Biodegradable
`Microcapsules: “Acceleration of Polymeric Excipient
`Hydrolytic Rate by Incorporation of a Basic Medicament',
`Journal of Controlled Release, Volume 3, 1986, pages
`103-117; hereinafter “the Maulding article'). The results
`reported in the Maulding article reveal that the degradation
`rate of DL-PL in ketotifen free base microcapsules was
`greater when the encapsulation process was carried out at 4
`C. than it was when the encapsulation proceSS was carried
`out at 25 C. In contrast, the degradation rate of DL-PL in
`thioridazine free base microcapsules was greater when the
`encapsulation process was carried out at 23° C. than it was
`when the encapsulation process is carried out at 4 C. Based
`on these results, the Maulding article Suggests circumvent
`ing the polymer degradation by carrying out the preparation
`of microcapsules at 4 C. in the case of thioridazine base.
`The Maulding article does not provide a method by which
`the molecular weight of the polymer in the finished micro
`particle can be conveniently controlled. Nor does the Maul
`ding article provide a method for preparing microparticles
`that have a Selected polymer molecular weight in the fin
`ished microparticle product.
`Thus, there is a need in the art for an improved method for
`preparing microparticles that controls the molecular weight
`
`1O
`
`15
`
`25
`
`35
`
`40
`
`45
`
`50
`
`55
`
`60
`
`65
`
`US 6,264,987 B1
`
`2
`of the polymer or polymeric matrix material in the finished
`microparticle product. There is a particular need in the art for
`an improved process that provides a method for preparing
`microparticles that have a Selected polymer molecular
`weight. The present invention, the description of which is
`fully set forth below, solves the need in the art for such an
`improved method.
`SUMMARY OF THE INVENTION
`The present invention relates to a method for preparing
`microparticles. The present invention allows microparticle
`products of varying polymer molecular weights to be pro
`duced using the same molecular weight Starting material.
`The present invention also allows microparticle products
`with Substantially the same polymer molecular weight to be
`produced from Starting materials of varying molecular
`weight. In one aspect of the invention, a method of preparing
`microparticles having a Selected microparticle polymer
`molecular weight is provided. The method comprises:
`(a) preparing a first phase, the first phase comprising a
`nucleophilic compound, a polymer having a Starting
`molecular weight, and a Solvent for the polymer;
`(b) combining the first phase with a second phase under
`the influence of mixing means to form an emulsion;
`(c) combining the emulsion and an extraction medium,
`thereby forming microparticles, and
`(d) maintaining the first phase at a hold temperature for a
`hold period prior to step (b), the hold period of Sufi
`cient duration to allow the Starting molecular weight of
`the polymer to reduce So that the Selected microparticle
`polymer molecular weight is achieved.
`In a further aspect of the present invention, another
`method for preparing microparticles is provided. The
`method comprises:
`(a) providing a polymer having a starting molecular
`weight;
`(b) dissolving the polymer and a nucleophilic compound
`in a Solvent to form a first phase;
`(c) combining the first phase with a second phase under
`the influence of mixing means to form an emulsion;
`(d) combining the emulsion and an extraction medium,
`thereby forming microparticles, and
`(e) maintaining the first phase at a hold temperature for a
`hold period prior to step (c), wherein the hold period is
`Selected So that the Starting molecular weight reduces
`So that a Selected microparticle polymer molecular
`weight is achieved.
`In other aspects of the present invention, the foregoing
`methods comprise adding an active agent to the first phase.
`In yet further aspects of the present invention, the foregoing
`methods comprise adding an inactive agent to the first phase.
`In further aspects of the invention, the hold temperature is
`increased, thereby increasing the molecular weight decay of
`the polymer to reduce the duration of the hold period. The
`hold temperature can be decreased, thereby decreasing the
`molecular weight decay of the polymer to increase the
`duration of the hold period.
`Other aspects of the present invention include a microen
`capsulated active agent and microparticles prepared by the
`methods of the present invention.
`Features and Advantages
`It is a feature of the present invention that it can be used
`to prepare microparticles, including microparticles contain
`ing an active agent.
`It is a further feature of the present invention that it allows
`the hold time and temperature of a nucleophilic compound/
`
`AMN1018
`IPR of Patent No. 7,919,499
`
`

`

`3
`polymer Solution to be modified to achieve a Selected
`polymer molecular weight in the microparticle product.
`An advantage of the present invention is that a Selected
`polymer molecular weight can be achieved in the micropar
`ticle product by using a variety of polymers, having varying
`Starting molecular weights, by varying the hold time of the
`nucleophilic compound/polymer Solution.
`A further advantage of the present invention is that
`microparticle products of varying polymer molecular
`weights can be produced using the same Starting polymer, or
`using a polymer having the same Starting molecular weight.
`BRIEF DESCRIPTION OF THE DRAWINGS
`The present invention is described with reference to the
`accompanying drawings. In the drawings, like reference
`numbers indicate identical or functionally Similar elements.
`FIG. 1 depicts a graph of molecular weight loSS percent
`age as a function of Solution hold time (hours) at a 1 kg
`Scale,
`FIG. 2 depicts a graph of molecular weight loSS percent
`age as a function of Solution hold time (hours) at a 20 kg
`Scale,
`FIG. 3 depicts a graph of molecular weight (kD) as a
`function of solution hold time (hours) at 15° C., 25 C., and
`35° C.; and
`FIG. 4 shows one embodiment of an equipment configu
`ration Suitable for preparing microparticles in accordance
`with the present invention.
`DETAILED DESCRIPTION OF THE DRAWINGS
`Overview
`The present invention provides an improved method for
`preparing microparticles. The methods of the present inven
`tion control the hold time and temperature of a polymer
`Solution in order to control the molecular weight of the
`polymer in the finished microparticle product. In this
`manner, the methods of the present invention advanta
`geously allow a Selected polymer molecular weight to be
`achieved from a variety of Starting material molecular
`weights. Alternatively, microparticle products of varying
`polymer molecular weights can be produced using the same
`molecular weight Starting material. Thus, a range of prod
`ucts can be made from the same Starting materials, thereby
`eliminating the need to reformulate the finished product to
`achieve the desired molecular weight of the polymer in the
`finished product.
`The polymer Solution used in the present invention com
`prises a nucleophilic compound. AS used herein, “nucleo
`philic compound” refers to a compound that promotes by
`nucleophilic catalysis the ester hydrolysis, Such as the poly
`mer Scission, that occurs in the biodegradation of biode
`gradable polymers, Such as polymers comprising varying
`lacotide:glycolide ratioS. A nucleophilic compound is a more
`effective nucleophile toward an ester group of the polymer
`than hydroxide ion or water. Nucleophilic compounds that
`catalyze the polymer hydrolysis include, but are not limited
`to, amines and carboxylate anions, and can be “active
`agents” (defined below) or “inactive agents” that are not
`active agents. Examples of nucleophilic compounds that are
`active agents include, but are not limited to, risperidone,
`9-hydroxyrisperidone, and pharmaceutically acceptable
`Salts of the foregoing, naltrexone, and oxybutynin.
`Examples of nucleophilic compounds that are inactive
`agents include, but are not limited to, protamine Sulfate,
`Spermine, choline, ethanolamine, diethanolamine, and tri
`ethanolamine. It should be readily apparent to be one skilled
`
`35
`
`40
`
`45
`
`50
`
`55
`
`60
`
`65
`
`US 6,264,987 B1
`
`15
`
`25
`
`4
`in the art that the present invention is not limited to any
`particular nucleophilic compound, and that the present
`invention encompasses other nucleophilic active agents and
`nucleophilic inactive agents.
`To ensure clarity of the description that follows, the
`following definitions are provided. By “microparticles” or
`“microSpheres' is meant particles that comprise a polymer
`that serves as a matrix or binder of the particle. The
`microparticle may contain an active agent or other Substance
`dispersed or dissolved within the polymeric matrix. The
`polymer is preferably biodegradable and biocompatible. By
`“biodegradable' is meant a material that should degrade by
`bodily processes to products readily disposable by the body
`and should not accumulate in the body. The products of the
`biodegradation should also be biocompatible with the body.
`By “biocompatible” is meant not toxic to the body, is
`pharmaceutically acceptable, is not carcinogenic, and does
`not significantly induce inflammation in body tissues. AS
`used herein, “body” preferably refers to the human body, but
`it should be understood that body can also refer to a
`non-human animal body. By “weight %' or “% by weight”
`is meant parts by weight per total weight of microparticle.
`For example, 10 wt.% active agent would mean 10 parts
`active agent by weight and 90 parts polymer by weight. By
`“controlled release microparticle' or “Sustained release
`microparticle' is meant a microparticle from which an active
`agent or other type of Substance is released as a function of
`time. By “mass median diameter' is meant the diameter at
`which half of the distribution (volume percent) has a larger
`diameter and half has a Smaller diameter.
`By “active agent' is meant an agent, drug, compound,
`composition of matter or mixture thereof which provides
`Some pharmacologic, often beneficial, effect. This includes
`foods, food Supplements, nutrients, drugs, Vitamins, and
`other beneficial agents. AS used herein, the terms further
`include any physiologically and pharmacologically active
`Substance that produces a localized or Systemic effect in a
`patient. Such active agents include antibiotics, antiviral
`agents, anepileptics, analgesics, anti-asthmatics, anti
`inflammatory agents and bronchodilators, and may be inor
`ganic and organic compounds, including, without limitation,
`drugs which act on the peripheral nerves, adrenergic
`receptors, cholinergic receptors, the Skeletal muscles, the
`cardiovascular System, Smooth muscles, the blood circula
`tory System, Synoptic Sites, neuroeffector junctional Sites,
`endocrine and hormone Systems, the immunological System,
`the reproductive System, the skeletal System, autacoid
`Systems, the alimentary and excretory Systems, the hista
`mine System and the central nervous System. Suitable agents
`may be selected from, for example, polysaccharides,
`Steroids, hypnotics and Sedatives, tranquilizers,
`anticonvulsants, muscle relaxants, antiparkinson agents,
`analgesics, anti-inflammatories, muscle contractants,
`antimicrobials, antimalarials, hormonal agents including
`contraceptives, Sympathomimetics, polypeptides and pro
`teins capable of eliciting physiological effects, diuretics,
`lipid regulating agents, antiandrogenic agents, leukotriene
`antagonists, antiparasites, neoplastics, antineoplastics,
`hypoglycemics, nutritional agents and Supplements, growth
`Supplements, fats, ophthalmics, antienteritis agents, electro
`lytes and diagnostic agents.
`Method and Examples
`The following examples are provided to explain the
`invention, and to describe the materials and methods used in
`carrying out the invention. The examples are not intended to
`limit the invention in any manner.
`
`AMN1018
`IPR of Patent No. 7,919,499
`
`

`

`S
`Molecular Weight Experiments with Nucleophilic Com
`pounds
`
`US 6,264,987 B1
`
`EXAMPLE 1.
`A Series of experiments were conducted at the 1 kg Scale
`that demonstrate the relationship between molecular weight
`of the finished microparticle product, and the duration of a
`hold period of a nucleophilic compound/polymer Solution.
`Microparticles comprising risperidone were prepared at the
`one-kilogram Scale. The 1. Kg process (400 grams of active
`agent and 600 grams of polymer) provides a theoretical drug
`loading of the microparticles of 40% (400 grams/1000
`gramsx100%).
`A 16.7 wt.% polymer solution was prepared by dissolv
`ing 600 grams of MEDISORB(R) 7525 DL polymer
`(Alkermes, Inc., Blue Ash, Ohio) in ethyl acetate. A 24 wt.
`% drug Solution was prepared by dissolving 400 grams of
`risperidone (basic nucleophilic active agent) (Janssen
`Pharmaceutica, Beerse, Belgium) in benzyl alcohol. A
`nucleophilic active agent/polymer Solution (organic phase)
`was prepared by mixing the drug Solution into the polymer
`Solution. The active agent/polymer Solution was maintained
`at a temperature of 25+5 C. The active agent/polymer
`Solution is held for a hold time of Sufficient duration to
`achieve the Selected or desired polymer molecular weight in
`the finished microparticle product, based on the Starting
`molecular weight of the polymer. The results of the
`experiments, showing the effect of hold time on molecular
`weight loSS, are discussed in more detail below with respect
`to Table 1 and FIG. 1.
`The Second, continuous phase was prepared by preparing
`a 30 liter solution of 1% polyvinyl alcohol (PVA), the PVA
`acting as an emulsifier. To this was added 2086 grams of
`ethyl acetate to form a 6.5 wt.% solution of ethyl acetate.
`The two phases were combined using a Static mixer, Such
`as a /2" Kenics Static mixer available from Chemineer, Inc.,
`North Andover, Mass. A total flow rate of 3 L/min generally
`provides microparticle Size distributions with a mass median
`diameter (MMD) in the range of about 80–90u. The ratio of
`continuous phase to discontinuous phase was 5:1 (v/v).
`The quench liquid was 2.5% solution of ethyl acetate and
`water-for-injection (WFI) at 5-10° C. The volume of the
`quench liquid is 0.25L per gram of batch size. The quench
`Step was carried out for a time period greater than about 4
`hours, with Stirring of the microparticles in the quench tank.
`After completion of the quench Step, the microparticles
`were collected, de-watered, and dried. The temperature was
`maintained at less than about 15 C.
`The microparticles were then re-slurried in a re-slurry
`tank using a 25% ethanol Solution. The temperature in the
`re-slurry tank was in the range of about 0° C. to about 15
`C. The microparticles were then transferred back to the
`quench tank for Washing for a time period of at least 6 hours
`with another extraction medium (25% ethanol solution) that
`was maintained at preferably 25+1 C.
`The microparticles were collected, de-watered, and dried.
`The temperature was warmed to greater than about 20° C.
`but below 40 C. Drying continued for a time period greater
`than about 16 hours.
`Twenty-four batches of risperidone microparticles at the 1
`kg Scale were prepared using the process described above.
`Table 1 below shows, for each batch, the starting molecular
`weight of the polymer (kD), the final molecular weight of
`the polymer in the finished microparticle product (kD), the
`percent loSS in molecular weight of the polymer, and the
`
`15
`
`25
`
`35
`
`40
`
`45
`
`50
`
`55
`
`60
`
`65
`
`6
`hold time (hours) of the active agent/polymer Solution. The
`molecular weight of the polymer in the finished micropar
`ticle product was determined by GPC.
`
`TABLE 1.
`
`Batchi
`
`Starting Mw Final Mw
`kD
`kD
`
`% Loss
`
`Hold time
`Hours
`
`825
`708
`71.4
`812
`819
`319
`331
`423
`SO6
`512
`52O
`527
`603
`610
`617
`902
`908
`921
`930
`915
`1021
`1028
`1110
`1215
`
`230
`61
`61
`61
`61
`31
`31
`31
`29
`29
`29
`29
`29
`29
`28
`28
`28
`28
`28
`92
`35
`38
`38
`38
`
`182
`110
`133
`1OO
`102
`110
`115
`78
`112
`86
`92
`95
`65
`101
`95
`85
`91
`99
`103
`69
`104
`119
`115
`111
`
`21.0
`32.O
`17.3
`37.9
`36.7
`16.2
`12.2
`40.7
`13.6
`33.7
`29.1
`26.8
`49.4
`22.0
`26.1
`33.8
`29.0
`23.2
`19.4
`24.8
`23.O
`13.7
`16.8
`19.4
`
`O.10
`2.08
`O.33
`2.40
`2.47
`O.10
`O.O7
`2.85
`O.O7
`3.10
`3.07
`2.22
`6.10
`1.13
`2.20
`1.90
`1.18
`O.08
`O.O3
`1.82
`O.O3
`O.45
`1.28
`1.50
`
`The data reported in Table 1 is depicted in the graph
`shown in FIG. 1. FIG. 1 shows an initial loss in molecular
`weight of approximately 17%, with an additional loss of
`approxamately 5.7% per hour of hold time of the active
`agent/polymer Solution.
`EXAMPLE 2
`Additional experiments were conducted at the 20 kg Scale
`that also demonstrate the relationship between molecular
`weight of the finished microparticle product, and the dura
`tion of a hold period of a nucleophilic compound/polymer
`Solution. Microparticles comprising risperidone were pre
`pared at the twenty-kilogram Scale. The 20 Kg process (8 kg
`of active agent and 12 kg of polymer) provides a theoretical
`drug loading of the microparticles of 40% (8 kg/20
`kgx100%).
`A 16.7 wt.% polymer solution was prepared by dissolv
`ing 12 kg of MEDISORB(R) 7525 DL polymer (Alkermes,
`Inc., Blue Ash, Ohio) in ethyl acetate. A 24 wt.% drug
`Solution was prepared by dissolving 8 kg of risperidone
`(Janssen Pharmaceutica, Beerse, Belgium) in benzyl alco
`hol. A nucleophilic active agent/polymer Solution (organic
`phase) was prepared by mixing the drug Solution into the
`polymer Solution. The active agent/polymer Solution was
`maintained at a temperature of 25+5 C. The active agent/
`polymer solution is held for a hold time of sufficient duration
`to achieve the Selected or desired polymer molecular weight
`in the finished microparticle product, based on the Starting
`molecular weight of the polymer. The results of the
`experiments, showing the effect of hold time on molecular
`weight loSS, are discussed in more detail below with respect
`to Table 2 and FIG. 2.
`The Second, continuous phase was prepared by preparing
`a 600 liter solution of 1% PVA, the PVA acting as an
`emulsifier. To this was added 42 kg of ethyl acetate to form
`a 6.5 wt.% solution of ethyl acetate. The two phases were
`combined using a Static mixer, Such as a 1" Kenics Static
`mixer available from Chemineer, Inc., North Andover,
`Mass.
`
`AMN1018
`IPR of Patent No. 7,919,499
`
`

`

`US 6,264,987 B1
`
`8
`ing from 30%-75%. The ambient polymer and drug solu
`tions were mixed together until a single homogeneous
`Solution (organic phase) was produced. The aqueous phase
`was at ambient conditions and contained 1% W/w polyvinyl
`alcohol and a Saturating amount of ethyl acetate. These two
`Solutions were pumped via positive displacement pumps at
`a ratio of 3:1 (aqueous:organic) through a /4" in-line mixer
`to form an emulsion. The emulsion was transferred to a
`Stirring Solvent extraction Solution consisting of 2.5% W/w
`of ethyl acetate dissolved in distilled water at 5-10 C. and
`at a volume of 0.5L of extraction solution per theoretical
`gram of microparticles. Both the polymer and drug Solvents
`were extracted into the extraction Solution from the emul
`Sion droplets to produce microparticles. The initial extrac
`tion proceSS ranged from two to four hours. The micropar
`ticles were collected on a 25 um Sieve and rinsed with a cold
`(<5 C.) 25% w/w ethanol solution. The microparticles were
`dried cold overnight (approximately 17 hours) using nitro
`gen. The microparticles were then transferred to the reslurry
`solution, which consisted of a vigorously stirring 25% w/w
`ethanol solution at 5-10°C. After a short mixing time (five
`to fifteen minutes), the reslurry Solution and the micropar
`ticles were transferred to a stirring 25% w/w ethanol sec
`ondary extraction Solution (approximately 25 C. at a Vol
`ume of 0.2 L of Secondary extraction Solution per theoretical
`gram of microparticles). The microparticles stirred for six
`hours enabling additional Solvent removal from the micro
`particles to take place. The microparticles were then col
`lected on a 25 um sieve and rinsed with a 25% w/w ethanol
`Solution at ambient temperature. These microparticles dried
`in a hood under ambient conditions overnight
`(approximately 17 hours), were sieved to remove agglom
`erated microparticles and then placed into a freezer for
`Storage.
`As shown below in Table 3, three batches of micropar
`ticles were prepared using the 75:25 polymer, two batches
`for the 85:15 polymer, and four batches for the 65:35
`polymer. For each batch, Table 3 shows the starting molecu
`lar weight of the polymer (kD), and the final molecular
`weight of the polymer in the finished microparticle products
`(kD), and the percent loss in molecular weight of the
`polymer. The molecular weight of the polymer in the fin
`ished microparticle product was determined by GPC. The
`data in Table 3 provides an example of the loSS in molecular
`weight of the polymer in a finished microparticle product
`containing a nucleophilic compound (naltrexone) for poly
`merS having varying lactide:glycolide ratioS.
`
`7
`The quench liquid was 2.5% solution of ethyl acetate and
`water-for-injection (WFI) at 5-10° C. The volume of the
`quench liquid is 0.25L per gram of batch size. The quench
`Step was carried out for a time period greater than about 4
`hours, with Stirring of the microparticles in the quench tank.
`After completion of the quench Step, the microparticles
`were collected, de-watered, and dried. The temperature was
`maintained at less than about 15 C.
`The microparticles were then re-slurried in a re-slurry
`tank using a 25% ethanol Solution. The temperature in the
`re-slurry tank was in the range of about 0° C. to about 15%
`microparticles were then transferred back to the quench tank
`for Washing for a time period of at least 6 hours with another
`extraction medium (25% ethanol solution) that was main
`tained at preferably 25+1° C.
`The microparticles were collected, de-watered, and dried.
`The temperature was greater than about 20° C. but below
`40° C. Drying continued for a time period about 16 hours.
`Four batches of risperidone microparticles at the 20 kg
`Scale were prepared using the proceSS described above.
`Table 2 below shows, for each batch, the starting molecular
`wieght of the polymer (kD), the final molecular weight of
`the polymer in the finished microparticle product (kD), the
`percent loSS in molecular weight of the polymer, and the
`hold time hours) of the active agent/polymer Solution. The
`molecular weight of the polymer in the finished micropar
`ticle product was determined by GPC.
`
`TABLE 2
`
`Batchi
`
`33O8
`4O68
`41.38
`4208
`
`Starting Mw Final Mw
`kD
`kD
`
`% Loss
`
`Hold time
`hours
`
`146
`145
`143
`143
`
`117
`103
`111
`110
`
`2O
`29
`22
`23
`
`0.5
`1.75
`1.O
`1.O
`
`The data reported in Table 2 show that from a relatively
`constant molecular Wieght starting material (143 kD, 145
`kD, and 146 kD), a variable finished microparticle product
`molecular weight was achieved by varying the hold time of
`the active agent/polymer Solution hold time. The data
`reported in Table 2 is depicted in the graph shown in FIG.
`2. FIG. 2 shows an initial loss in molecular weight of
`approximately 16%, with an additional loSS of approxi
`mately 7.3% per hour of hold time of the active agent/
`polymer Solution.
`
`15
`
`25
`
`35
`
`40
`
`45
`
`50
`
`EXAMPLE 3
`The starting molecular weight of the polymer (kD) and
`the final molecular weight of the polymer in a finished
`microparticle product (kD) was determined for micropar
`ticles containing the nucleophilic compound naltrexone. The
`starting polymer lactide:glycolide ratio was 75:25, 85:15,
`55
`and 65:35. The polymers used were MEDISORB(R) 7525 DL
`polymer, MEDISORB(R 8515 DL polymer and MEDIS
`ORB(R 6535 DL polymer, all available from Alkermes, Inc.,
`Blue Ash, Ohio.
`The naltrexone base microparticles were produced using
`a co-Solvent extraction process. The theoretical batch size
`was 15 to 20 grams. The polymer was dissolved in ethyl
`acetate to produce a 16.7% w/w polymer solution. The
`naltrexone base anhydrous was dissolved in benzyl alcohol
`to produce a 30.0% w/w solution. In various batches, the
`amount of drug and polymer used was varied to produce
`microparticles with different theoretical drug loading rang
`
`60
`
`65
`
`TABLE 3
`
`Starting Polymer
`Lactide:glycolide ratio Batch
`
`Starting Mw Final Mw
`kD
`kD
`
`% Loss
`
`75:25
`
`85:15
`
`65:35
`
`99-123-004
`99-123-009
`99-123-012
`99-123-O16
`99-123-024
`99-123-021
`99-123-O28
`99-123-037
`99-123-034
`
`116.2
`116.2
`116.2
`109.7
`109.7
`102.3
`102.3
`102.3
`102.3
`
`76.O
`74.O
`74.3
`83.7
`74.9
`56.3
`63.4
`69.6
`79.6
`
`34.6
`36.3
`36.1
`23.7
`31.7
`45.O
`38.O
`32.O
`22.2
`
`EXAMPLE 4
`Additional experiments were conducted with other poly
`mers that also demonstrate the relationship between molecu
`lar weight of the finished microparticle product, and the
`duration of a hold period of a nucleophilic compound/
`
`AMN1018
`IPR of Patent No. 7,919,499
`
`

`

`US 6,264,987 B1
`
`10
`be seen in Table 5, the longer the exposure or hold time of
`the drug/polymer Solution, the lower the molecular weight
`of the polymer.
`
`polymer Solution. Microparticles comprising other polymers
`having different lactide:glycolide ratios were prepared.
`Microparticles comprising risperidone using polymerS hav
`ing lactide:glycolide ratios of 65:35, 85:15, and 100:0 were
`prepared at the 1. Kg Scale using the Same process described
`above in Example 1. The polymers used were MEDIS
`ORB(R 6535 DL polymer, MEDISORB(R) 8515 DL polymer,
`and MEDISORB(R) 100 DL polymer, all available from
`Alkermes, Inc., Blue Ash, Ohio.
`Table 4 below shows, for each polymer, the Starting
`molecular weight of the polymer (kD), the final molecular
`weight of the polymer in the finished microparticle product
`(kD), the percent loss in molecular weight of the polymer,
`and the hold time (hours) of the active agent/polymer
`solution. The molecular weight of the polymer in the fin
`ished microparticle product was determined by GPC.
`
`15
`
`TABLE 4
`
`Lactide:glycolide
`ratio
`
`Starting Mw Final Mw
`kD
`kD
`
`% Loss
`
`Hold time
`hours
`
`65:35
`85:15
`100 di
`
`105
`112
`105
`
`79
`96
`98
`
`24.8
`14.3
`6.7
`
`0.27
`O.23
`0.17
`
`The data reported in Table 4 show that a microparticle
`product having about the same molecular weight (96 kD and
`98 kD) can be prepared from two different molecular weight
`polymers (112 kD and 105 kD, respectively) having two
`different lactide:glycolide ratios (85:15 and 100:0,
`respectively). The present invention thus advantageously
`allows microparticle products with the same polymer
`molecular weight to be produced using two different starting
`materials.
`
`EXAMPLE 5
`Additional experiments were conducted that demonstrate
`the molecular weight loSS of polymers in the presence of a
`nucleophilic compound (oxybutynin) as a function of time.
`Tests were conducted using a 100:0 lactide:glycolide poly
`mer and two 75:25 lactide:glycolide polymers with differing
`inherent Viscosity. For each test, the following protocol was
`carried out. Weigh about 6 g polymer into an Erlenmeyer
`flask. Add to the polymer 44 g ethyl acetate, Sonicate and
`shake to dissolve the polymer. Weigh 1.5g oxybutynin base.
`Stir the polymer Solution, and add the drug to the polymer
`Solution. Start the timer as the drug is added. Sample the
`drug/polymer Solution at 1, 5 and 15 minutes, taking about
`/3 of the original Volume for each aliquot as the Solution
`stirs. Dispense the aliquot into 250 mL 50:50 H.O:MeOH,
`and Stir. This mix precipitates the polymer and removes the
`drug from the precipitate. Allow precipitated polymer to
`Settle and decant the Supernatant. Wash polymer residue
`with 100mL MeOH, stir approximately one minute, add up
`to 250 mL H2O. Allow polymer to s